MGF Molecular Structure & Chemical Properties

Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor-1 (IGF-1) that has been investigated in preclinical research since its discovery in 1996. First identified in skeletal muscle subjected to mechanical stress, MGF represents one of several IGF-1 isoforms produced through alternative splicing of the IGF-1 gene. Unlike the predominant liver-derived IGF-1Ea isoform, MGF (designated IGF-1Ec in humans and IGF-1Eb in rodents) contains a unique 49-base pair insert that results in a reading frame shift, producing a distinctive C-terminal E-domain peptide sequence. This structural modification appears to confer tissue-specific repair functions distinct from systemic IGF-1 actions, though the complete mechanism remains under investigation.

Note: MGF does not have a standard PubChem CID entry as it is a splice variant peptide. The structure is best represented by its amino acid sequence.

Technical Specifications

The MGF peptide sequence contains multiple basic residues (lysine and arginine) contributing to its positive charge and potential interaction with cellular receptors. The unique E-domain distinguishes MGF from mature IGF-1 and appears critical for its tissue-specific repair activities.

MGF Mechanism of Action

MGF peptide exerts biological effects through mechanisms that appear distinct from, yet complementary to, canonical IGF-1 receptor signaling. Research suggests that satellite cell activation serves as the primary driver of MGF’s tissue repair effects, though the exact receptor and signaling pathways remain incompletely characterized. Current evidence indicates MGF may function through both receptor-mediated and potentially intracrine (nuclear) mechanisms.

Primary Cellular Pathways

Satellite Cell Activation – Muscle Repair

Studies demonstrate that MGF expression increases dramatically following muscle damage or mechanical overload, with peak levels occurring before satellite cell activation. Research in rodent models shows:

• Enhanced proliferation of muscle satellite cells without immediate differentiation
• Increased myogenic precursor cell populations in injured muscle
• Delayed senescence of satellite cells from young donors
• Greater fusion potential of activated satellite cells into existing muscle fibers

The temporal relationship between MGF upregulation and satellite cell activation suggests a causative role in initiating muscle repair processes.

PI3K and MAPK Pathway Modulation

Investigations in osteoblast and chondrocyte models indicate MGF influences multiple downstream signaling cascades. Key findings include:

• Activation of PI3K/Akt pathway promoting cell survival and protein synthesis
• MAPK-Erk1/2 pathway stimulation driving proliferation responses
• Enhanced phosphorylation patterns distinct from mature IGF-1 effects
• Cell cycle progression through S and G2/M phases in proliferating cells

These pathways appear to mediate MGF’s pro-proliferative effects across multiple tissue types beyond muscle.

Nuclear Localization and Intracrine Action

Recent evidence suggests MGF or its E-domain peptide may possess nuclear activity independent of membrane receptor activation:

• Nuclear localization observed in mechanically stimulated cells
• Potential interaction with transcription factors including Nrf2
• Activation of heme oxygenase-1 for oxidative stress protection
• Effects that occur without canonical IGF-1 receptor engagement

This nuclear mechanism could explain MGF’s neuroprotective actions observed in brain ischemia models.

Angiogenic Activity

Research demonstrates MGF peptide promotes blood vessel formation through:

• Stimulation of vascular endothelial cell proliferation and migration
• Enhanced tube formation in endothelial cell models
• Improved vascularization in ischemic tissue
• Complementary but distinct effects compared to VEGF signaling

Anti-Apoptotic Signaling

Studies in cardiac and chondrocyte models show MGF modulates cell survival pathways:

• Upregulation of anti-apoptotic Bcl-2 expression
• Downregulation of pro-apoptotic Bax and caspase-3
• Protection against apoptosis under mechanical stress
• Maintenance of cardiac function following myocardial infarction in animal models

MGF Research Applications & Key Findings

Musculoskeletal Tissue Research

Skeletal Muscle Repair and Hypertrophy

Extensive preclinical investigations have examined MGF’s role in muscle regeneration. Key findings from animal studies include:

• 25% increase in mean muscle fiber size following 3 weeks of intramuscular MGF injection in mouse models
• Enhanced satellite cell activation following cardiotoxin-induced injury in rat tibialis anterior muscle
• Increased proliferation without premature differentiation in C2C12 myoblast cell lines
• Improved muscle mass retention in aged animals with impaired endogenous MGF peptide expression

Studies using synthetic MGF peptides demonstrated dose-dependent proliferative effects, with optimal responses at nanomolar concentrations in cell culture systems.

Tendon and Ligament Healing

Research in rabbit models examined MGF’s effects on tendon repair:

• Accelerated healing in Achilles tendon injury models
• Enhanced collagen organization at repair sites
• Improved tensile strength measurements in healing tendons
• Increased growth factor expression including type I collagen

Cartilage and Bone Research

Investigations in orthopedic applications demonstrated:

• Protection of chondrocytes from mechanical stress-induced apoptosis
• Promotion of osteoblast proliferation through MAPK-Erk1/2 pathway
• Enhanced bone defect healing in rabbit radius segmental defect models
• Regulation of inflammatory cytokines in osteoarthritis models (decreased IL-1beta and TNF-alpha)

Studies showed MGF maintained cartilage homeostasis under normalized mechanical loading conditions.

Cardiovascular Research

Cardiac Protection Studies

Research in large animal (sheep) myocardial infarction models showed:

• 35% reduction in cardiomyocyte damage when MGF administered post-infarction
• Improved cardiac function measurements by echocardiography
• Reduced infarct size compared to vehicle-treated controls
• Maintenance of left ventricular function 8 days post-MI

The MGF E-domain peptide alone demonstrated protective effects comparable to full-length MGF in these models.

Central Nervous System Research

Neuroprotection Studies

Investigations in brain ischemia and neurological injury models demonstrated:

• Nearly complete protection against motor neuron loss in rabbit facial nerve avulsion models when MGF administered locally
• Significant neuroprotective effects in brain ischemia experiments
• Increased neurogenesis in aging mouse hippocampus and subventricular zones
• Enhanced proliferation of neural progenitor cells

Studies in transgenic mice with MGF overexpression showed increased BrdU-positive proliferative cells in neurogenic brain regions.

Aging and Sarcopenia Research

Research examining age-related muscle loss revealed:

• Progressive decline in endogenous MGF expression with advancing age
• Impaired ability to upregulate MGF in response to mechanical overload in elderly subjects
• Age-dependent differences in satellite cell response to synthetic MGF peptide
• Enhanced proliferative lifespan of satellite cells from young but not old adult muscle

These findings suggest age-related impairment in MGF expression may contribute to sarcopenia pathogenesis.

MGF Pharmacokinetics & Metabolism

Absorption & Distribution

MGF exhibits extremely unfavorable pharmacokinetic properties in its native form, presenting significant challenges for therapeutic development. Studies in animal models indicate:

• Plasma half-life under 10 minutes for unmodified MGF peptide
• Rapid enzymatic degradation by peptidases in circulation
• Limited systemic distribution due to instability
• Requirement for local delivery or chemical modification for sustained activity

Research using pegylated MGF (PEG-MGF) demonstrated substantially improved pharmacokinetics, with half-life extension to 48-72 hours enabling systemic circulation and tissue targeting.

Metabolism & Elimination

The metabolic fate of MGF remains poorly characterized, but available research suggests:

• Rapid proteolytic cleavage by circulating peptidases
• Potential cleavage of E-domain from pro-IGF-1 precursor in vivo
• Unknown contribution of intact peptide versus metabolites to biological effects
• Insufficient data on specific enzymatic pathways involved in degradation

A critical knowledge gap exists regarding whether endogenously produced MGF functions primarily as an intact splice variant or requires processing to release the bioactive E-domain peptide.

Excretion Pathways

Limited pharmacokinetic data on MGF elimination pathways indicates:

• Presumed renal clearance of peptide fragments following degradation
• No evidence of accumulation with repeated dosing in animal studies
• Rapid clearance preventing sustained systemic effects without modification
• PEGylation dramatically altering excretion kinetics

The disconnect between MGF’s short plasma half-life and prolonged biological effects (lasting hours to days) in some tissue injury models suggests either local tissue retention, sustained signaling cascade activation, or alternative pharmacodynamic mechanisms not yet elucidated.

MGF Research Protocols & Administration

Dosing in Published Research

Preclinical investigations have employed diverse MGF doses depending on species, model, and peptide form:

• Rat studies: 200 nM intramuscular injection for muscle injury studies; variable systemic doses
• Mouse models: 1-5 micrograms per muscle for intramuscular delivery; transgenic overexpression models
• Rabbit studies: 28.5-57 micrograms per kg body weight for bone healing research (5 consecutive days)
• Sheep models: 200 nM MGF for cardiac protection studies
• Cell culture: 0.1-10 nM concentrations with optimal proliferative effects at 1 nM

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to profound differences in peptide metabolism, receptor density and distribution, proteolytic enzyme activity, and pharmacokinetic parameters. MGF’s extremely short half-life and species-specific splice variants further complicate any cross-species dosing predictions.

Administration Routes in Research

Multiple delivery methods have been investigated with variable success:

• Intramuscular injection – Most common route for skeletal muscle studies; enables local delivery to target tissue
• Local injection at injury site – Used in tendon, nerve, and cardiac studies for site-specific effects
• Subcutaneous injection – Limited use due to rapid degradation
• Gene delivery via viral vectors – Adenoviral and transgenic expression systems to achieve sustained MGF levels
• Pegylated formulations – PEG-MGF enables systemic delivery with extended half-life

The short half-life of native MGF necessitates frequent dosing, local delivery, or chemical modification for most research applications.

Common Model Organisms

MGF has been studied across multiple species and systems:

• Mice – Primary model for muscle regeneration, neurogenesis, aging studies; transgenic overexpression models
• Rats – Muscle injury, tendon healing, disc degeneration, and chondrocyte research
• Rabbits – Bone healing, tendon repair, nerve injury protection studies
• Sheep – Cardiac protection following myocardial infarction
• Cell culture – C2C12 myoblasts, primary human satellite cells, MC3T3-E1 osteoblasts, chondrocytes, endothelial cells, cardiomyocytes

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite significant preclinical research interest since 1996, MGF faces substantial barriers that limit its research utility and prevent any clinical development.

Lack of Human Clinical Data

The most significant limitation is the complete absence of human research:

• No peer-reviewed human clinical trials exist in scientific literature
• No Phase I safety studies published or registered in clinical trial databases
• Human safety profile completely unestablished
• Optimal human dosing unknown and unpredictable from animal data
• Long-term effects in humans completely unstudied
• No data on individual variability in response

Fundamental Mechanistic Uncertainties

Critical aspects of MGF biology remain unresolved despite decades of research:

• Primary receptor not definitively identified – whether MGF binds a novel receptor, modified IGF-1 receptor, or functions through alternative mechanisms remains debated
• Relative contribution of intact MGF versus cleaved E-domain peptide to biological effects unknown
• Nuclear versus membrane receptor-mediated mechanisms incompletely understood
• Endogenous processing and whether MGF exists as a stable protein in vivo remains questioned
• Tissue-specific mechanisms and differential effects across organs require clarification

Controversial Research Findings

The MGF research field has been marked by significant scientific controversy:

• Major 2013 study from pharmaceutical companies found synthetic MGF peptide had no proliferative effects on muscle myoblasts or primary satellite cells, directly contradicting earlier findings
• Inconsistent results across laboratories regarding MGF’s mechanism and potency
• Debate over whether observed effects result from MGF itself or contaminating mature IGF-1
• Questions about whether MGF represents a functionally distinct entity or a transient mRNA product

These controversies have limited confidence in translating preclinical findings.

Long-Term Safety Considerations

Critical safety questions remain completely unaddressed:

• Chronic use effects unstudied even in animal models beyond several weeks
• Potential for dysregulated cell proliferation or tumor promotion unknown
• Effects on cancer cell growth or metastasis uninvestigated
• Drug interaction potential uncharacterized
• Optimal duration of treatment undefined
• Off-target effects in non-injured tissues unexplored

Regulatory & Competitive Sport Status

FDA Position

MGF has not received FDA approval for any indication:

• Classified as an unapproved drug substance
• Not recognized as safe and effective for any use
• Not approved for human or veterinary applications
• Not legally available for medical compounding in the United States
• No established therapeutic use basis
• Exists in regulatory gray area as research chemical only

MGF cannot be legally prescribed, compounded, or marketed for human consumption.

WADA Prohibition

The World Anti-Doping Agency has prohibited MGF since 2005:

• Listed under Section S2.2 (Peptide Hormones, Growth Factors, and Related Substances)
• Prohibited at all times (both in and out of competition)
• No Therapeutic Use Exemptions (TUEs) available
• Classified alongside other growth factors with performance-enhancing potential
• Detection methods have been developed for anti-doping testing
• Full-length MGF and synthetic peptide analogs all prohibited

WADA’s early prohibition reflected concerns about potential misuse despite lack of human efficacy data.

Research Classification: MGF is available only for laboratory research use. It is not intended for human consumption, medical use, veterinary applications, or athletic performance enhancement. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Yang, S.Y., Alnaqeeb, M., Simpson, H., & Goldspink, G. (1996). Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. Journal of Muscle Research and Cell Motility, 17(5), 487-495. PubMed
   
2. Matheny, R.W., Nindl, B.C., & Adamo, M.L. (2010). Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology, 151(3), 865-875. PubMed
   
3. Kandalla, P.K., Goldspink, G., Butler-Browne, G., & Mouly, V. (2011). Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 132(4), 154-162. PubMed
   
4. Yang, S.Y., & Goldspink, G. (2002). Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Letters, 522(1-3), 156-160. PubMed
   
5. Hameed, M., Orrell, R.W., Cobbold, M., Goldspink, G., & Harridge, S.D. (2003). Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. Journal of Physiology, 547(Pt 1), 247-254. PubMed
   
6. Deng, M., Zhang, B., Wang, K., Liu, F., Xiao, H., Zhao, J., et al. (2011). Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. International Orthopaedics, 35(7), 1099-1106. PubMed
   
7. Carpenter, V., Matthews, K., Devlin, G., Stuart, S., Jensen, J., Conaglen, J., et al. (2008). Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart, Lung and Circulation, 17(1), 33-39. PubMed
   
8. Dluzniewska, J., Sarnowska, A., Beresewicz, M., Johnson, I., Srai, S.K., Ramesh, B., et al. (2005). A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB Journal, 19(13), 1896-1898. PubMed
   
9. Aperghis, M., Johnson, I.P., Cannon, J., Yang, S.Y., & Goldspink, G. (2004). Different levels of neuroprotection by two insulin-like growth factor-I splice variants. Brain Research, 1009(1-2), 213-218. PubMed
   
10. Mills, P., Dominique, J.C., Lafreniere, J.F., Bouchentouf, M., & Tremblay, J.P. (2007). A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. American Journal of Transplantation, 7(10), 2247-2259. PubMed
    
11. Owino, V., Yang, S.Y., & Goldspink, G. (2001). Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (MGF) in response to mechanical overload. FEBS Letters, 505(2), 259-263. PubMed
    
12. Goldspink, G. (2005). Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping. British Journal of Sports Medicine, 39(11), 787-788. PubMed
    
13. Sun, K.T., Cheung, K.K., Au, S.W., Yeung, S.S., & Yeung, E.W. (2018). Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury. Frontiers in Physiology, 9, 999. PubMed
    
14. Cui, H., Yi, Q., Feng, J., Yang, L., & Tang, L. (2014). Mechano growth factor E peptide regulates migration and differentiation of bone marrow mesenchymal stem cells. Journal of Molecular Endocrinology, 52(2), 111-120. PubMed
    
15. Fornaro, M., Hinken, A.C., Needle, S., Hu, E., Trendelenburg, A.U., Mayer, A., et al. (2014). Mechano-growth factor peptide (MGF), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. American Journal of Physiology-Endocrinology and Metabolism, 306(4), E390-E401. PubMed
    
16. Zablocka, B., Goldspink, P.H., Goldspink, G., & Gorecki, D.C. (2012). Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Frontiers in Endocrinology, 3, 131. PubMed
    
17. Xu, Q., Fang, H., Zhao, L., Zhang, C., Zhang, L., & Tian, B. (2019). Mechano growth factor attenuates mechanical overload-induced nucleus pulposus cell apoptosis through inhibiting the p38 MAPK pathway. Bioscience Reports, 39(3), BSR20182462. PubMed
    
18. Thevis, M., Ogorzalek Loo, R.R., & Loo, J.A. (2014). Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Rapid Communications in Mass Spectrometry, 28(9), 1097-1103. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. MGF is intended for laboratory research use only.